Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs
Bailey Pemberton
Thu, August 13, 2026 at 8:42 PM GMT+5:30
2 min read
- NVO
+0.71%
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide
Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK’s MHRA approves Eli Lilly’s oral weight loss therapy Foundayo for use in the country
The approval adds a non injectable option alongside Novo Nordisk’s GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings
In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk and Eli Lilly medications
These developments highlight changing access and pricing dynamics in obesity care that may influence volumes and reimbursement for Novo Nordisk’s flagship treatments
Novo Nordisk is far from the only stock tied into this kind of healthcare and infrastructure build out, so it can be useful to compare it with the broader set available through 55 AI infrastructure stocks
Novo Nordisk, a pharmaceuticals group with a DKK1.3 trillion market cap, focuses on researching, manufacturing and distributing treatments for chronic conditions such as obesity and diabetes. As oral and lower cost weight loss options emerge, investors are watching how the company positions its existing GLP 1 portfolio in this broader obesity care market
Is Novo Nordisk’s balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis
What the Foundayo approval and Amazon program really test in the Novo Nordisk Narrative
The Novo Nordisk Narrative is built on GLP-1 leadership expanding into convenient pills and new access channels, while holding on to pricing power and earnings quality. The UK approval of Eli Lilly’s Foundayo and Amazon’s low fixed Medicare pricing both push directly on that trade off
“Growing pricing pressures, generic competition, and rising costs threaten margins, revenue growth, and earnings stability despite Novo Nordisk’s leadership in obesity and diabetes therapies…”
Read the full Novo Nordisk narrativeto see the case behind these numbers
The MHRA green light for Lilly’s oral Foundayo goes straight to the core bet that Novo Nordisk can extend its GLP-1 leadership into pills and implants. It reinforces the Narrative’s risk that pricing pressure could bite as more oral options arrive, especially if NICE backs either drug for broad NHS use
Amazon Pharmacy’s US$50 Medicare program points to the other side of the story. Access may widen for both Novo Nordisk and Eli Lilly, yet the flat fee structure speaks directly to analysts’ concerns about lower realised prices and higher non cash items affecting earnings quality that is already flagged as a risk
